{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:49:06Z","timestamp":1783957746432,"version":"3.55.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013152","name":"Shanghai Institute of Materia Medica Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["SIMM0120231001"],"award-info":[{"award-number":["SIMM0120231001"]}],"id":[{"id":"10.13039\/501100013152","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.intimp.2025.116026","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T16:17:08Z","timestamp":1765642628000},"page":"116026","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Targeting Cbl-b by a small molecular inhibitor potentiates T cell receptor signaling and suggests rational combination strategies"],"prefix":"10.1016","volume":"169","author":[{"given":"Yuantong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haotian","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingshan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianfeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2025.116026_bb0005","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.cell.2023.02.039","article-title":"Advances in cancer immunotherapies","volume":"186","author":"Dagher","year":"2023","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.intimp.2025.116026_bb0010","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"issue":"10304","key":"10.1016\/j.intimp.2025.116026_bb0015","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2025.116026_bb0020","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T cell dysfunction in cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.intimp.2025.116026_bb0025","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","article-title":"Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways","volume":"19","author":"Kraehenbuehl","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.intimp.2025.116026_bb0030","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1016\/j.cell.2021.07.029","article-title":"Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer","volume":"184","author":"Goc","year":"2021","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.intimp.2025.116026_bb0035","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","article-title":"Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy","volume":"27","author":"Pitt","year":"2016","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.intimp.2025.116026_bb0040","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/13543776.2021.1924671","article-title":"Inhibitors of immuno-oncology target HPK1 - a patent review (2016 to 2020)","volume":"31","author":"Linney","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.intimp.2025.116026_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114819","article-title":"The development of small-molecule inhibitors targeting HPK1","volume":"244","author":"Zhou","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.intimp.2025.116026_bb0050","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/s41573-022-00538-9","article-title":"The expanding role for small molecules in immuno-oncology","volume":"21","author":"Offringa","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.intimp.2025.116026_bb0055","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006007","article-title":"Targeting Cbl-b in cancer immunotherapy","volume":"11","author":"Augustin","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.116026_bb0060","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/ni1416","article-title":"Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cell-mediated immune responses","volume":"8","author":"Shui","year":"2007","journal-title":"Nat. Immunol."},{"issue":"41","key":"10.1016\/j.intimp.2025.116026_bb0065","doi-asserted-by":"crossref","first-page":"34091","DOI":"10.1074\/jbc.M112.371062","article-title":"Attenuation of T cell receptor signaling by serine phosphorylation-mediated lysine 30 ubiquitination of SLP-76 protein","volume":"287","author":"Wang","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2025.116026_bb0070","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/bs.ai.2015.09.006","article-title":"MAP4K family kinases in immunity and inflammation","volume":"129","author":"Chuang","year":"2016","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.intimp.2025.116026_bb0075","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.55122","article-title":"A perspective on HPK1 as a novel immuno-oncology drug target","volume":"9","author":"Sawasdikosol","year":"2020","journal-title":"Elife"},{"issue":"10","key":"10.1016\/j.intimp.2025.116026_bb0080","doi-asserted-by":"crossref","first-page":"6187","DOI":"10.4049\/jimmunol.0802631","article-title":"Hematopoietic progenitor kinase 1 is a negative regulator of dendritic cell activation","volume":"182","author":"Alzabin","year":"2009","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2025.116026_bb0085","doi-asserted-by":"crossref","first-page":"7349","DOI":"10.4049\/jimmunol.1000576","article-title":"Macroautophagy regulates energy metabolism during effector T cell activation","volume":"185","author":"Hubbard","year":"2010","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2025.116026_bb0090","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nri2161","article-title":"Unveiling the roles of autophagy in innate and adaptive immunity","volume":"7","author":"Levine","year":"2007","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2025.116026_bb0095","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.immuni.2012.04.008","article-title":"Selective autophagy of the adaptor protein Bcl10 modulates T cell receptor activation of NF-\u03baB","volume":"36","author":"Paul","year":"2012","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.intimp.2025.116026_bb0100","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","article-title":"Clonal replacement of tumor-specific T cells following PD-1 blockade","volume":"25","author":"Yost","year":"2019","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.116026_bb0105","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13045-018-0578-4","article-title":"Lessons learned from the blockade of immune checkpoints in cancer immunotherapy","volume":"11","author":"Li","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2025.116026_bb0110","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s12276-020-0435-8","article-title":"Recent insights of T cell receptor-mediated signaling pathways for T cell activation and development","volume":"52","author":"Hwang","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.intimp.2025.116026_bb0115","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-061020-053702","article-title":"Cytokine regulation and function in T cells","volume":"39","author":"Dong","year":"2021","journal-title":"Annual Reviews of Immunology"},{"issue":"7237","key":"10.1016\/j.intimp.2025.116026_bb0120","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nature07959","article-title":"Ubiquitylation in innate and adaptive immunity","volume":"458","author":"Bho","year":"2009","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.intimp.2025.116026_bb0125","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1002\/eji.200939662","article-title":"E3 ubiquitin ligases in T-cell tolerance","volume":"39","author":"Paolino","year":"2009","journal-title":"Eur. J. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2025.116026_bb0130","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nri1731","article-title":"Immunity by ubiquitylation: a reversible process of modification","volume":"5","author":"Liu","year":"2005","journal-title":"Nat. Rev. Immunol."},{"issue":"6766","key":"10.1016\/j.intimp.2025.116026_bb0135","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/35003228","article-title":"Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b","volume":"403","author":"Bachmaier","year":"2000","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.intimp.2025.116026_bb0140","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/ni855","article-title":"C-Cbl and Cbl-b regulate T cell responsiveness by promoting ligand-induced TCR down-modulation","volume":"3","author":"Naramurar","year":"2002","journal-title":"Nat. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2025.116026_bb0145","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1016\/j.immuni.2023.11.010","article-title":"TCR signaling promotes formation of an STS1-Cbl-b complex with pH-sensitive phosphatase activity that suppresses T cell function in acidic environments","volume":"56","author":"Tsai","year":"2023","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2025.116026_bb0150","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.immuni.2010.07.002","article-title":"K33-linked polyubiquitination of T cell receptor-zeta regulates proteolysis-independent T cell signaling","volume":"33","author":"Huang","year":"2010","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.intimp.2025.116026_bb0155","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.immuni.2004.07.013","article-title":"Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction","volume":"21","author":"Jeon","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2025.116026_bb0160","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ceca.2017.01.014","article-title":"Calcium-NFAT transcriptional signalling in T cell activation and T cell exhaustion","volume":"63","author":"Hogan","year":"2017","journal-title":"Cell Calcium"},{"issue":"7","key":"10.1016\/j.intimp.2025.116026_bb0165","doi-asserted-by":"crossref","first-page":"8959","DOI":"10.1096\/fj.201902811RR","article-title":"PTPN22 interacts with EB1 to regulate T-cell receptor signaling","volume":"34","author":"Zhang","year":"2020","journal-title":"FASEB J."},{"issue":"4","key":"10.1016\/j.intimp.2025.116026_bb0170","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1158\/2326-6066.CIR-20-0973","article-title":"Overproduction of IFN\u03b3 by Cbl-b-deficient CD8+ T cells provides resistance against regulatory T cells and induces potent antitumor immunity","volume":"10","author":"Han","year":"2022","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.116026_bb0175","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/cei.13560","article-title":"E3 ubiquitin ligase casitas B lineage lymphoma-b and its potential therapeutic implications for immunotherapy","volume":"204","author":"Jafari","year":"2021","journal-title":"Clinical Experimental Immunology"},{"issue":"4","key":"10.1016\/j.intimp.2025.116026_bb0180","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/10409238.2017.1325829","article-title":"Ubiquitin enzymes in the regulation of immune responses","volume":"52","author":"Ebner","year":"2017","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"issue":"34","key":"10.1016\/j.intimp.2025.116026_bb0185","doi-asserted-by":"crossref","first-page":"57163","DOI":"10.18632\/oncotarget.18714","article-title":"Cbl-b predicts postoperative survival in patients with resectable pancreatic ductal adenocarcinoma","volume":"8","author":"Dong","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.intimp.2025.116026_bb0190","first-page":"59","article-title":"Expression of c-Cbl, Cbl-b, and epidermal growth factor receptor in gastric carcinoma and their clinical significance, Chin J","volume":"29","author":"Dong","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.intimp.2025.116026_bb0195","doi-asserted-by":"crossref","first-page":"1432545","DOI":"10.3389\/fphar.2024.1432545","article-title":"The role of CBL family ubiquitin ligases in cancer progression and therapeutic strategies","volume":"15","author":"Ren","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2025.116026_bb0200","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/s42003-023-05655-8","article-title":"The co-crystal structure of Cbl-b and a small-molecule inhibitor reveals the mechanism of Cbl-b inhibition","volume":"6","author":"Kimani","year":"2023","journal-title":"Commun Biol"},{"issue":"Suppl. 13","key":"10.1016\/j.intimp.2025.116026_bb0205","article-title":"Small molecule inhibition of the ubiquitin ligase CBL-B results in potent T and NK cell mediated anti-tumor response","volume":"81","author":"Rountree","year":"2021","journal-title":"Cancer Res."},{"issue":"W1","key":"10.1016\/j.intimp.2025.116026_bb0210","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.intimp.2025.116026_bb0215","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nri1330","article-title":"Jurkat T cells and development of the T-cell receptor signalling paradigm","volume":"4","author":"Abraham","year":"2004","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.116026_bb0220","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s12864-018-4718-6","article-title":"A genome-wide survey of mutations in the Jurkat cell line","volume":"19","author":"Gioia","year":"2018","journal-title":"BMC Genomics"},{"issue":"1","key":"10.1016\/j.intimp.2025.116026_bb0225","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1038\/s41467-024-48014-9","article-title":"HPK1 citron homology domain regulates phosphorylation of SLP76 and modulates kinase domain interaction dynamics","volume":"15","author":"Chitre","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2025.116026_bb0230","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.1038\/s41598-017-06002-8","article-title":"Molecular mechanism of PD-1\/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab","volume":"7","author":"Lee","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.intimp.2025.116026_bb0235","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1021\/acs.jmedchem.3c01361","article-title":"Rising star in immunotherapy: development and therapeutic potential of small-molecule inhibitors targeting casitas B cell lymphoma-b (Cbl-b)","volume":"67","author":"Zhou","year":"2024","journal-title":"J. Med. Chem."},{"issue":"37","key":"10.1016\/j.intimp.2025.116026_bb0240","doi-asserted-by":"crossref","first-page":"16274","DOI":"10.1073\/pnas.1007575107","article-title":"Rapidly fatal myeloproliferative disorders in mice with deletion of casitas B-cell lymphoma (Cbl) and Cbl-b in hematopoietic stem cells","volume":"107","author":"Naramura","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"33","key":"10.1016\/j.intimp.2025.116026_bb0245","doi-asserted-by":"crossref","first-page":"14709","DOI":"10.1073\/pnas.1009209107","article-title":"T-cell regulation by casitas B-lineage lymphoma (Cblb) is a critical failsafe against autoimmune disease due to autoimmune regulator (Aire) deficiency","volume":"107","author":"Teh","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.intimp.2025.116026_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117488","article-title":"Rational design, optimization, and biological evaluation of novel pyrrolo-pyridone derivatives as potent and orally active Cbl-b inhibitors","volume":"290","author":"Zhang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"17","key":"10.1016\/j.intimp.2025.116026_bb0255","doi-asserted-by":"crossref","first-page":"18670","DOI":"10.1021\/acs.jmedchem.5c01820","article-title":"Discovery of phosphorylated Peptidomimetics targeting Cbl-b SH2 domain as Orthosteric Cbl-b inhibitors by an optimized fluorescence polarization competition assay","volume":"68","author":"Li","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.intimp.2025.116026_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113971","article-title":"Cbl-b inhibition improves manufacturing efficiency and antitumoral efficacy of anti-CD19 CAR-T cells","volume":"147","author":"Wang","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2025.116026_bb0265","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12441","article-title":"Anti-cancer therapy with TNF\u03b1 and IFN\u03b3: a comprehensive review","volume":"51","author":"Shen","year":"2018","journal-title":"Cell Prolif."},{"issue":"4","key":"10.1016\/j.intimp.2025.116026_bb0270","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","article-title":"CD8 T cell states in human cancer: insights from single-cell analysis","volume":"20","author":"van der Leun","year":"2020","journal-title":"Nat. Rev. Cancer"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925020156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925020156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:57:17Z","timestamp":1768510637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925020156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":54,"alternative-id":["S1567576925020156"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.116026","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting Cbl-b by a small molecular inhibitor potentiates T cell receptor signaling and suggests rational combination strategies","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.116026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"116026"}}